Zhejiang Jingxin Pharmaceutical

What Zhejiang Jingxin Pharmaceutical does

Zhejiang Jingxin Pharmaceutical Co., Ltd. (浙江京新药业股份有限公司) is a publicly listed Chinese pharmaceutical company (Shenzhen Stock Exchange: 002020) founded in 1990 and headquartered in Xinchang County, Zhejiang Province. The company integrates research and development, manufacturing, and commercial sales across two main business segments: (1) pharmaceutical products including finished dosage forms, active pharmaceutical ingredients (APIs), and intermediates, with therapeutic focus on psychiatry/neurology, cardiovascular, and digestive tract diseases; and (2) medical display devices, produced through its wholly-owned subsidiary Shenzhen Jufeng Display Technology Co., Ltd., which manufactures diagnostic, surgical, clinical, and ultrasound medical displays.

The company operates EU GMP and US FDA certified manufacturing facilities and runs one of China's largest contract manufacturing (CMO) platforms for oral solid dosage forms, exporting billions of tablets annually to European, US, and Japanese markets while serving multiple Global Top50 pharmaceutical clients. Jingxin has completed more than 50 molecule technology transfers with 40+ products commercially supplied globally, supported by its own API production facilities through Shaoxing Jingxin and Shangyu Jingxin subsidiaries and a 3 billion tablet annual capacity expansion brought online in February 2024. The company has invested in or cooperatively established 10 companies and R&D laboratories internationally and has secured patents including a Rosuvastatin Calcium synthesis process that won a provincial science and technology first prize.

Zhejiang Jingxin's revenue model combines one-time sales of proprietary pharmaceutical products and APIs (domestic and export), CMO contract manufacturing services with multi-year contracts for global pharma companies, and hardware sales of medical display devices through its subsidiary. In 2024, the company launched its first Class 1 innovative drug, Jingnuoning Didencetin capsules for insomnia, which was included in the 2024 National Medical Insurance Drug List, and followed with the first domestic market approval of Cariprazine Hydrochloride for adult schizophrenia in July 2026. Domestic distribution was expanded through an April 2024 strategic partnership with Jointown Pharmaceutical Group for retail and third/fourth-terminal market reach, and the Hangzhou headquarters officially opened in September 2024 to support internationalization and innovation transformation. As of 2024, total assets stood at 8.124 billion CNY with 3,700+ employees.

Name

Zhejiang Jingxin Pharmaceutical

Legal name

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Website

https://jingxinpharm.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Zhejiang Jingxin Pharmaceutical is a Shenzhen-listed Chinese pharma company (founded 1990) that develops, manufactures, and sells generic and innovative CNS, cardiovascular, and GI drugs, APIs, and medical display devices, with a large CMO platform exporting oral solid dosage forms to global pharma clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Contract manufacturing services
• Medical display devices
• Generic drug development

Headquarters

HQ city

Xinchang

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Manufacturing and sales of pharmaceutical finished dosage forms including drugs for cardiovascular, cerebrovascular, digestive tract and psychology/psychiatry treatment areas. Core business with domestic and export sales.
2. Active Pharmaceutical Ingredients (API): Production and export of pharmaceutical raw materials and intermediates
3. CMO Contract Manufacturing: Contract manufacturing services for oral solid dosage (OSD) forms including tablets and capsules for global pharmaceutical companies. Major exporter of formulations with annual export volume reaching billions of tablets.
4. Medical Devices: Medical display products through subsidiary Shenzhen Juyi Display Technology Co., Ltd., covering diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens and ultrasonic medical displays.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Zhejiang Jingxin Pharmaceutical manufactures and sells finished dosage pharmaceutical products (tablets and capsules), active pharmaceutical ingredients (APIs), and pharmaceutical intermediates, with therapeutic focus on psychiatry/neurology, cardiovascular, and digestive tract areas. The company also provides CMO (Contract Manufacturing Organization) services for oral solid dosage forms to global pharmaceutical companies exporting to Europe, US and Japan, and produces medical display devices through its subsidiary Shenzhen Juyi Display Technology.

Product overview

Zhejiang Jingxin Pharmaceutical is a listed pharmaceutical company integrating R&D, production and sales. The company operates two core business segments: (1) Pharmaceutical products including drug formulations, active pharmaceutical ingredients (APIs), and intermediates, with focus therapeutic areas in psychiatry/neurology, cardiovascular, and digestive tract; and (2) Medical devices through subsidiary Shenzhen Juyi Display Technology, specializing in medical display equipment for hospital imaging applications. Key products include innovative drugs such as 京诺宁®地达西尼胶囊 (sleep disorder treatment) and 盐酸卡立哌嗪胶囊 (antipsychotic), along with a broad portfolio of generic drugs and APIs. The company also offers CMO contract manufacturing services for oral solid dosage forms.

Differentiator

Problem solved

Functional benefit

Brands

• 京诺宁® (JNDN/Didencetin): Class 1 innovative drug for insomnia treatment, containing didencetin as active ingredient
• 盐酸卡立哌嗪胶囊 (Cariprazine hydrochloride)

Products and services

• Drug Products (药品) Core pharmaceutical finished dosage products including chemical preparations, traditional Chinese medicines, and biological preparations, with therapeutic focus on psychiatry/neurology, cardiovascular, and digestive tract treatment areas. Targeted at hospitals, pharmacies, and patients in domestic and international markets.
• Active Pharmaceutical Ingredients (原料药) Active pharmaceutical ingredients including quinolone anti-infectives, cardiovascular drugs, and psychiatry/neurology medications. Includes APIs such as simvastatin, levofloxacin, ciprofloxacin hydrochloride, enrofloxacin, and rosuvastatin calcium. Targeted at global pharmaceutical companies for further formulation and export markets.
• Pharmaceutical Intermediates (中间体) Pharmaceutical intermediates used in the production of active pharmaceutical ingredients. Targeted at API manufacturers and pharmaceutical companies.
• Medical Devices (医疗器械) — Medical Displays Medical display products covering diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, and ultrasonic medical displays for DR, CR, angiography, CT, MRI, ultrasound, and endoscopy equipment. Targeted at hospitals and medical imaging facilities.
• CMO Contract Manufacturing Services (合同生产服务) Contract manufacturing services for oral solid dosage forms (OSD) including tablets and capsules. Wide batch size range from tens of kg/batch to tons/batch with diverse manufacturing processes including powder direct compression, one-step granulation, wet granulation, dry granulation, pellet coating, and minitabs compression. One of the largest CMO manufacturing service suppliers for OSD in China, exporting to European, US and Japan markets. Targeted at global pharmaceutical companies requiring outsourced manufacturing.
• Jingnuoning® Didansini Capsules (京诺宁®地达西尼胶囊) Class 1 innovative drug for sleep disorders. The first self-developed innovative drug for insomnia treatment. Targeted at insomnia patients and prescribed through hospital channels in China.
• Cariprazine Hydrochloride Capsules (盐酸卡立哌嗪胶囊) Atypical antipsychotic drug, dopamine D2/D3 receptor partial agonist for the treatment of adult schizophrenia. Specifications: 1.5mg and 3mg. First domestic market approval in China. Targeted at hospitals and patients requiring schizophrenia treatment.
• Aspirin Enteric-Coated Tablets (阿司匹林肠溶片) Aspirin enteric-coated tablets selected for the 10th batch of national drug centralized procurement in China. Targeted at cardiovascular patients and healthcare providers.

Quantifiable outcome

• First Chinese enterprise to use EU Serialization packaging on large scale
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and strategic.

• Zhejiang University (浙江大学)coreStrategic or Co-development Partner · 17 April 2026Partnership with Zhejiang University School of Public Administration to establish pharmaceutical affairs class for talent development. The 1.5-year program with 32 courses covers pharmaceutical regulations, policy trends, full-process management, AI applications, and digital transformation. Aims to cultivate compound talents with systematic thinking for the company's innovation transformation and internationalization goals.
• STADAstrategicStrategic or Co-development Partner · 10 February 2025STADA team visited Jingxin on February 10, 2025 and was warmly received by Chairman Lu Gang. The team visited exhibition hall, research institute, laboratory, production workshop and automated overhead warehouse to understand Jingxin's industrial layout, production advantages and quality management. High praise given for product diversification strategy and refined production facility management, laying foundation for future cooperation.
• Jointown Pharmaceutical Group (九州通医药集团)coreChannel Partner/ Reseller/ Distributor · 22 April 2024Strategic partnership signed on April 22, 2024 for retail market distribution. Jointown has transformed from product distributor to service provider, focusing on retail, third terminal and fourth terminal markets outside hospitals. The partnership leverages Jingxin's hospital market product advantages and Jointown's marketing capabilities to expand Jingxin's external market presence.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Regional players

• Livzon Pharmaceutical Group: Chinese pharmaceutical company with specialty focus on CNS, digestive, and reproductive health products. Overlapping therapeutic categories with Jingxin's CNS and digestive tract portfolio, though with somewhat different geographic and channel emphasis.

Direct peers

• Apeloa Pharmaceutical: Zhejiang-based API and formulation manufacturer with significant CMO/CDMO operations. Comparable in API vertical integration and international export orientation, competes for global pharmaceutical contract manufacturing customers.
• Huahai Pharmaceutical: Chinese pharmaceutical company with strong CNS/prantipsychotic portfolio and significant international generic drug presence. Direct competitor in CNS therapeutic categories with comparable FDA-cleared manufacturing and US export orientation.
• Zhejiang Hisun Pharmaceutical: Zhejiang-based Chinese pharmaceutical company with similar API and finished formulation business. Comparable scale with focus on anti-infectives and specialty generics, direct competitor in international API markets with overlapping customer base of global generic pharma companies.
• Shandong Luoxin Pharmaceutical: Chinese pharmaceutical company with strong CNS and respiratory therapeutic focus. Direct competitor in central nervous system treatments, particularly antipsychotic and antidepressant categories where Jingxin competes with Cariprazine and other CNS products.

Others

• STADA Arzneimittel: German specialty pharmaceutical company focused on generics and consumer health products. Strategic partner and potential CMO customer of Jingxin; comparable in CNS generic focus and serves as both customer and competitive benchmark in European markets.

Broad incumbents

• CSPC Pharmaceutical Group: Large Hong Kong-listed Chinese pharmaceutical company with extensive CNS portfolio and innovative drug pipeline. Significantly larger than Jingxin but operates in overlapping therapeutic areas including neurology and oncology.
• Fosun Pharma: Diversified Chinese pharmaceutical conglomerate with API manufacturing, finished formulations, and international presence. Competes across multiple Jingxin segments including API exports and CNS treatments, with broader geographic and product portfolio.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharmaceutical company with extensive R&D pipeline and CNS, oncology, and anesthesia focus. Operates across same therapeutic categories as Jingxin but at much greater scale and innovation intensity.
• Aurobindo Pharma: Major Indian pharmaceutical company with significant API and finished formulation manufacturing, strong US and European generic drug presence. Competes with Jingxin in CMO services and generic pharmaceutical exports to Western markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zhejiang-jingxin-pharmaceutical-co-ltd-

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhejiang Jingxin Pharmaceutical